MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
55.37
-0.28
-0.50%
After Hours: 55.00 -0.37 -0.67% 19:57 07/24 EDT
OPEN
56.07
PREV CLOSE
55.65
HIGH
56.34
LOW
55.11
VOLUME
1.84M
TURNOVER
--
52 WEEK HIGH
57.57
52 WEEK LOW
33.76
MARKET CAP
13.92B
P/E (TTM)
18.35
1D
5D
1M
3M
1Y
5Y
1D
Exelixis Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $53
Benzinga · 1d ago
Morgan Stanley Issues a Hold Rating on Exelixis (EXEL)
TipRanks · 1d ago
Arcus in supply deal with AVEO Oncology for casdatifan combo in kidney cancer
Seeking Alpha · 2d ago
Press Release: Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
Dow Jones · 2d ago
Exelixis schedules quarterly results release and investor call
PUBT · 2d ago
The Credit Cycle Is Flashing Yellow
Seeking Alpha · 2d ago
Weekly Report: what happened at EXEL last week (0713-0717)?
Weekly Report · 4d ago
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.